The European Haemophilia Consortium (EHC) will hold its first Round Table of Stakeholders of 2017 on Tuesday 7 March on the topic of Clinical Trials.

What: EHC Round Table of Stakeholders on Clinical Trials

When: Tuesday 7 March 2017 from 13.00 to 16.00 hrs – registrations start at 12.15 hrs

Where: European Parliament, Brussels, Belgium

For whom: All

Language of the event: English

Registrations: Online here

Event agenda: Consult the programme of the event

More information: Contact laura.savini[at]ehc.eu


About the event

The European Haemophilia Consortium (EHC) is delighted to invite you to its first Round Table of Stakeholder of the year, which will be held in Brussels on Tuesday 7 March 2017 from 13.00 till 16.00 hrs.

With a number of novel therapies being developed for the treatment of haemophilia A, we found it appropriate to hold our first event of the year on the topic of ‘Clinical Trials in Haemophilia A.’ During this event, we are hoping to tackle the issue of long-term safety for novel medicinal products. To do so, we have invited a series of speakers as outlined here below.

Prof Frits Rosendaal from the University of Leiden (NL) will explain how epidemiological data in haemophilia is collected. As long-term safety is a critical issue with novel therapies, Prof Johannes Oldenburg (Bonn University, DE) will give an overview of how long-term observation of efficacy for novel therapies is carried out in haemophilia. This presentaiton will be complemented by a talk from Prof Flora Peyvandi (University of Milan, IT, and a member of the EHC Medical Advisory Group) who will talk about safety of novel haemophilia therapies.
We will hear from a representative from the European Medicines Agency (EMA) on how novel therapies are evaluated by this agency. To conclude, Prof Pier-Mannuccio Mannucci (University of Milan, IT) will talk about previously untreated patients (PUPs) in clinical trials.